UNSPSC 51392215: Tolonidine

This classification denotes an alpha-adrenergic agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I4O795Q03O. European Medicines Agency schedules Tolonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11167MIG. Tolonidine generally arises in the molecular formula C10H12CLN3. The term TOLONIDINE is an International Non-Proprietary Name or INN. TOLONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule tolonidine under HS 29332990 and SITC 51573. As of Q4 2014, TOLONIDINE remains the US FDA Preferred Term for this commodity. Tolonidine bears US NLM identifiers UMLS ID C0076803 and NCI Concept Code C75048. SMILES: CC1=CC(=C(C=C1)NC2=NCCN2)CL.

UNSPSC 51392215 Tolonidine is a Commodity code that covers the procurement of pharmaceutical products, specifically tolonidine and related pharmaceutical items. However, the recent state and local opportunities tagged under this code show a significant mismatch: Seminole County, Florida and the Texas Health and Human Services Commission are soliciting naloxone (an opioid antagonist), safe drug deactivation systems, and direct-to-manufacturer prescription services—none of which are tolonidine. The code shows little activity aligned with its nominal pharmaceutical scope. Issuing bodies include county health departments (Seminole County) and state health and human services agencies (Texas HHS), representing typical health-sector purchasers seeking pharmaceutical inventory and pharmacy program innovation.

The geographic concentration is limited to Florida and Texas in recent postings. Seminole County issued an Invitation for Bid (IFB) on June 30, 2026 (due July 26, 2023—note the date discrepancy in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The mismatch between the tolonidine code and the actual pharmaceutical products being solicited suggests either a coding error in the state procurement system or that tolonidine itself does not reflect current state and local pharmaceutical purchasing patterns.